 The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer HRPC, and to determine the safety and activity profile of a single dose of cytotoxic chemotherapy docetaxel in combination with MDX-010 